Physician profile
Jonathan Ram
NPI 1750648572
$3,177.53
in general payments reported to CMS, 2019-2025
15 companies · $88.16 in 2025
The $88.16 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $99.22 · 2021: $740 · 2022: $1,217 · 2023: $25.34 · 2024: $465 · 2025: $88.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,575.12 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $568.73 | 2020-2024 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.33 | 2019-2024 | Ofev |
| Insmed, INC. | $154.65 | 2019 | |
| Genentech USA, INC. | $140.85 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $140.49 | 2024-2025 | Dupixent, Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $64.95 | 2024 | Glassia |
| Genzyme Corporation | $60.65 | 2024-2025 | |
| Mylan Specialty L.P. | $52.07 | 2024 | Yupelri |
| Philips North America LLC | $32.50 | 2024 | (Ak6) Vest Therapy |
| Viatris Specialty LLC | $28.65 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $25.34 | 2023 | Xarelto |
| Ani Pharmaceuticals, INC. | $24.04 | 2024 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $14.96 | 2024 | Trelegy Ellipta |
| Amgen INC. | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.